SunTrust Robinson analyst David S Macdonald reiterated a Buy rating on Amedisys (NASDAQ: AMED) yesterday and set a price target of $118. The company’s shares opened today at $103.85, close to its 52-week high of $108.92.
According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 14.7% and a 72.6% success rate. Macdonald covers the Services sector, focusing on stocks such as Encompass Health Corporation, Walgreens Boots Alliance, and WellCare Health Plans.
Currently, the analyst consensus on Amedisys is a Moderate Buy with an average price target of $97.50, implying a -6.1% downside from current levels. In a report issued on July 31, Jefferies also reiterated a Buy rating on the stock with a $120 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $108.92 and a one-year low of $45.60. Currently, Amedisys has an average volume of 290.3K.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.
